{"id":14761,"date":"2023-12-21T09:40:12","date_gmt":"2023-12-21T08:40:12","guid":{"rendered":"https:\/\/www.adas.org.rs\/?p=14761"},"modified":"2025-11-18T15:34:02","modified_gmt":"2025-11-18T14:34:02","slug":"finalist-bostonskog-maratona-dobio-je-trogodisnju-suspenziju-zbog-dopinga","status":"publish","type":"post","link":"https:\/\/www.adas.org.rs\/en\/iz_medija\/2023\/12\/21\/finalist-bostonskog-maratona-dobio-je-trogodisnju-suspenziju-zbog-dopinga\/","title":{"rendered":"Boston Marathon finisher receives three-year doping suspension"},"content":{"rendered":"<p><\/p>\n<p>(runningmagazine.ca) On Thursday, the Athletics Integrity Unit (AIU) announced the suspension of Kenyan marathoner Maurine Chepkemoi after she tested positive for erythropoietin (EPO) on Nov. 3 during an out-of-competition doping test in Iten, Kenya.<\/p>\n<p>Chepkemoi has a marathon personal best of 2:20:18 from a second-place finish at the 2021 Amsterdam Marathon. Since 2021, she has won the Enschede Marathon in the Netherlands in a course record time of 2:21:10 and finished 16th at the 2022 Berlin Marathon and 31st at the 2023 Boston Marathon in 2:35:25&#8230;<\/p>\n<p>https:\/\/runningmagazine.ca\/the-scene\/boston-marathon-finisher-receives-three-year-doping-suspension\/<\/p>","protected":false},"excerpt":{"rendered":"<p>(runningmagazine.ca) On Thursday, the Athletics Integrity Unit (AIU) announced the suspension of Kenyan marathoner Maurine Chepkemoi after she tested positive for erythropoietin (EPO) on Nov. 3 during an out-of-competition doping test in Iten, Kenya. Chepkemoi has a marathon personal best of 2:20:18 from a second-place finish at the 2021 Amsterdam Marathon. Since 2021, she has <a href=\"https:\/\/www.adas.org.rs\/en\/iz_medija\/2023\/12\/21\/finalist-bostonskog-maratona-dobio-je-trogodisnju-suspenziju-zbog-dopinga\/\" class=\"more-link\">&#8230;<span class=\"screen-reader-text\">  Boston Marathon finisher receives three-year doping suspension<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-14761","post","type-post","status-publish","format-standard","hentry","category-iz_medija"],"_links":{"self":[{"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/posts\/14761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/comments?post=14761"}],"version-history":[{"count":2,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/posts\/14761\/revisions"}],"predecessor-version":[{"id":16779,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/posts\/14761\/revisions\/16779"}],"wp:attachment":[{"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/media?parent=14761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/categories?post=14761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.adas.org.rs\/en\/wp-json\/wp\/v2\/tags?post=14761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}